PMOS: a new name for a common condition
2026-09-03
PMOS enters medicine as a quiet rebuke to the older label PCOS. The new term, short for polyendocrine metabolic ovarian syndrome, argues that the condition is not about cysts at all but about a network of hormone disturbances that begin in the ovaries and radiate through the body.
Central to PMOS is the claim that naming shapes care. Under the former polycystic ovary syndrome label, diagnosis often leaned on ultrasound images and the misleading presence or absence of so called cysts, even though the core pathology rests in hyperandrogenism and chronic anovulation, driven by altered gonadotropin secretion and insulin resistance in many patients.
More ambitious is the word polyendocrine in the new title. It signals that multiple hormone axes are involved, including the hypothalamic pituitary ovarian axis and broader metabolic pathways that govern glucose homeostasis and adipose tissue function, placing PMOS squarely within discussions of cardiometabolic risk rather than limiting it to reproductive complaints.
Clinicians argue that this reframing carries practical consequences. A diagnosis of PMOS pushes attention toward endocrine evaluation, long term metabolic monitoring and individualized risk reduction, using tools such as oral glucose tolerance testing and lipid profiling, rather than a narrow focus on menstrual regulation or cosmetic management of excess hair growth.
Loading...
